IL17A and atherosclerosis: Interferon, a key immune function regulator, is highly expressed in atherosclerotic lesions, and mouse studies indicate that T and B-cell deficiency reduces the atherosclerotic burden during the development of atherosclerotic lesions and that regulation of the IL-17 signaling pathway may play a role in the pathogenesis of several inflammatory and autoimmune diseases, including atherosclerosis (Chen et al., 2010; Fan et al., 2016; Lu, 2017).